111 related articles for article (PubMed ID: 4038746)
1. Thromboxane synthetase inhibitors (TXSI). Design, synthesis, and evaluation of a novel series of omega-pyridylalkenoic acids.
Kato K; Ohkawa S; Terao S; Terashita Z; Nishikawa K
J Med Chem; 1985 Mar; 28(3):287-94. PubMed ID: 4038746
[TBL] [Abstract][Full Text] [Related]
2. CV-4151--a potent, selective thromboxane A2 synthetase inhibitor.
Terashita Z; Imura Y; Tanabe M; Kawazoe K; Nishikawa K; Kato K; Terao S
Thromb Res; 1986 Jan; 41(2):223-37. PubMed ID: 3083523
[TBL] [Abstract][Full Text] [Related]
3. Thromboxane synthetase inhibitors: design and synthesis of a novel series of omega-pyridylalkenoic acids.
Terao S; Kato K; Ohkawa S; Terashita Z; Nishikawa K
Adv Prostaglandin Thromboxane Leukot Res; 1985; 15():315-7. PubMed ID: 2936112
[No Abstract] [Full Text] [Related]
4. Imidazo[1,5-a]pyridines: a new class of thromboxane A2 synthetase inhibitors.
Ford NF; Browne LJ; Campbell T; Gemenden C; Goldstein R; Gude C; Wasley JW
J Med Chem; 1985 Feb; 28(2):164-70. PubMed ID: 3918169
[TBL] [Abstract][Full Text] [Related]
5. Highly selective inhibitors of thromboxane synthetase. 2. Pyridine derivatives.
Tanouchi T; Kawamura M; Ohyama I; Kajiwara I; Iguchi Y; Okada T; Miyamoto T; Taniguchi K; Hayashi M; Iizuka K; Nakazawa M
J Med Chem; 1981 Oct; 24(10):1149-55. PubMed ID: 7199089
[TBL] [Abstract][Full Text] [Related]
6. 6,6-Disubstituted Hex-5-enoic acid derivatives as combined thromboxane A2 receptor antagonists and synthetase inhibitors.
Soyka R; Heckel A; Nickl J; Eisert W; Müller TH; Weisenberger H
J Med Chem; 1994 Jan; 37(1):26-39. PubMed ID: 8289199
[TBL] [Abstract][Full Text] [Related]
7. Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 3. Pyridinylalkyl-substituted 8-[(arylsulfonyl)amino]octanoic acids.
Main AJ; Bhagwat SS; Boswell C; Goldstein R; Gude C; Cohen DS; Furness P; Lee W; Louzan M
J Med Chem; 1992 Nov; 35(23):4366-72. PubMed ID: 1447737
[TBL] [Abstract][Full Text] [Related]
8. Thromboxane receptor antagonism combined with thromboxane synthase inhibition. 1. (+/-)-(3-pyridinylbicycloheptyl)alkanoic acids.
Bhagwat SS; Gude C; Cohen DS; Lee W; Furness P; Clarke FH
J Med Chem; 1991 Jun; 34(6):1790-7. PubMed ID: 1829485
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of thromboxane synthetase potentiates the antihypertensive action of an angiotensin-converting enzyme inhibitor by a prostaglandin-dependent but kinin-independent mechanism.
Levens NR; Cóte D; Ksander G
J Pharmacol Exp Ther; 1991 Oct; 259(1):219-27. PubMed ID: 1920118
[TBL] [Abstract][Full Text] [Related]
10. Effects of dietary n-3 fatty acid supplementation versus thromboxane synthetase inhibition on gentamicin-induced nephrotoxicosis in healthy male dogs.
Grauer GF; Greco DS; Behrend EN; Fettman MJ; Mani I; Getzy DM; Reinhart GA
Am J Vet Res; 1996 Jun; 57(6):948-56. PubMed ID: 8725828
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase.
Hibi S; Okamoto Y; Tagami K; Numata H; Kobayashi N; Shinoda M; Kawahara T; Harada K; Miyamoto K; Yamatsu I
J Med Chem; 1996 Aug; 39(16):3148-57. PubMed ID: 8759636
[TBL] [Abstract][Full Text] [Related]
12. Characterization of imidazo[1,5-a]pyridine-5-hexanoic acid (CGS 13080) as a selective thromboxane synthetase inhibitor using in vitro and in vivo biochemical models.
Ku EC; McPherson SE; Signor C; Chertock H; Cash WD
Biochem Biophys Res Commun; 1983 May; 112(3):899-906. PubMed ID: 6687803
[TBL] [Abstract][Full Text] [Related]
13. Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition--I. Synthesis, structure-activity relationship, and evaluation of substituted omega-phenyl-omega-(3-pyridyl)alkenoic acids.
Takeuchi K; Happ AM; Mais DE; Layman N; Utterback BG; Wyss VL; Jakubowski JA
Bioorg Med Chem; 1994 Aug; 2(8):743-55. PubMed ID: 7894968
[TBL] [Abstract][Full Text] [Related]
14. 3-(1-imidazolylmethyl) indoles: potent and selective inhibitors of human blood platelet thromboxane synthetase.
Cross PE; Dickinson RP; Parry MJ; Randall MJ
Agents Actions; 1981 May; 11(3):274-80. PubMed ID: 7020379
[TBL] [Abstract][Full Text] [Related]
15. Development of dual-acting agents for thromboxane receptor antagonism and thromboxane synthase inhibition. 3. Synthesis and biological activities of oxazolecarboxamide-substituted omega-phenyl-omega-(3-pyridyl)alkenoic acid derivatives and related compounds.
Takeuchi K; Kohn TJ; True TA; Mais DE; Wikel JH; Utterback BG; Wyss VL; Jakubowski JA
J Med Chem; 1998 Dec; 41(27):5362-74. PubMed ID: 9876106
[TBL] [Abstract][Full Text] [Related]
16. The thromboxane A2/prostaglandin endoperoxide receptor antagonist activity of CV-4151, a thromboxane A2 synthetase inhibitor.
Imura Y; Terashita Z; Shibouta Y; Nishikawa K
Eur J Pharmacol; 1988 Mar; 147(3):359-65. PubMed ID: 2967770
[TBL] [Abstract][Full Text] [Related]
17. CGS 12970: a novel, long acting thromboxane synthetase inhibitor.
Ambler J; Butler KD; Ku EC; Maguire ED; Smith JR; Wallis RB
Br J Pharmacol; 1985 Oct; 86(2):497-504. PubMed ID: 2932197
[TBL] [Abstract][Full Text] [Related]
18. (E)-7-Phenyl-7-(3-pyridyl)-6-heptenoic acid (CV-4151): a potent, specific thromboxane A2 synthetase inhibitor.
Nishikawa K; Terashita Z; Imamoto T; Imura Y; Hirata M; Terao S
Adv Prostaglandin Thromboxane Leukot Res; 1985; 15():523-5. PubMed ID: 2936160
[No Abstract] [Full Text] [Related]
19. Guanidine derivatives as combined thromboxane A2 receptor antagonists and synthase inhibitors.
Soyka R; Guth BD; Weisenberger HM; Luger P; Müller TH
J Med Chem; 1999 Apr; 42(7):1235-49. PubMed ID: 10197967
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
